Introduction
Androgen deprivation therapy (ADT) is the initial treatment of choice for men with metastatic prostate cancer for the past several years. [1] Although ADT is palliative, it can normalize serum levels of prostate-specific antigen (PSA) in over 90% of patients and can produce objective tumor responses in 80%-90%. This antitumor activity can improve quality of life by reducing bone pain as well as the rates of complications (e.g., pathologic fracture, spinal cord compression, and ureteral obstruction). [2, 3] The duration of response to ADT for patients with metastatic disease is highly variable, and most patients eventually progressed to metastatic castrate resistant prostate cancer (mCRPC), although such patients may remain responsive to additional therapies directed against androgenic stimulation of the prostate cancer.
A unique molecular alteration in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations. [4] [5] [6] Other alterations include overexpression of androgen receptors, and androgen receptor mutations leading to androgen-receptor binding by additional ligands that would not stimulate the wild-type receptor. [7, 8] This has led to the development of drugs which act by inhibition of the enzymes responsible for androgen production, as well as those which inhibit the androgen receptor. Abiraterone acetate (AA), a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17, a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor. Two randomized phase III trial COU-AA-301 and 302 have demonstrated the efficacy of AA in patients of castrate-resistant prostate cancer in both postdocetaxel and chemo-naïve patients. We report the clinical outcome of metastatic castration-resistant prostate cancer patients treated with AA in real-life clinical practice at our institute. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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Results

Characteristics of patients' cohort
A total of 59 patients were reviewed, of whom 37 were chemo-naïve and 22 were postchemotherapy. Table 1 summarizes the characteristics of the patient cohort. The median follow-up duration was 10 months (2.7, 29.6) and 15 months (3.6, 48.1) for chemo-naïve and postchemotherapy group, respectively. The mean age of the study cohort was 67 years. Comorbidities such as diabetes mellitus, hypertension, and ischemic heart disease were present in 17 (28.8%), 30 (50.8%), and 10 (16.9%) of patients, respectively. Median baseline PSA and Gleason score was 132.5 and 8, respectively. A total of 9 out of 59 patients were diagnosed with localized disease at the time of initial presentation and underwent definitive surgery [4] or radical radiotherapy. [5] These patients also received ADT when they developed metastatic disease. A total of 19 out of 59 (32.2%) patients opted for medical castration and rest of the patient underwent surgical orchidectomy for ADT. At the time of starting AA, visceral disease (lymph node and visceral organ metastases) was present in 16 (43.2%) chemo-naïve and 8 (36.36%) postchemo patients. About 85% of patients were symptomatic for disease, and 14 out of 59 patients received ketoconazole before initiation of AA.
Clinical efficacy
Prostate-specific antigen response
The proportion of patients with best PSA response is 4 (18.1%) in postchemo groups and 15 (39.4%) in chemo-naïve group [ Table 1 ]. Median time to best PSA response was 3.4 months, with 3/38 chemo-naïve, and 0/22 postchemo patients were still under treatment at the time of the last follow-up. Disease progression was the major reason of treatment discontinuation.
Overall survival and progression-free survival
The median OS and progression-free survival for the complete cohort were 11.9 (95% confidence interval [CI]: 10, 17) months and 6.7 (95% CI: 5.5, 9.9) months, respectively. The patients with visceral disease had numerically inferior OS (9.7 vs. 12.8 months) and inferior PFS (5.8 vs. 8.7 months) than those without visceral disease, which was not statistically significant (P value 0.088 and 0.25). The median OS and PFS was 15 months (95% CI: 11.4, 28.1) and 7.8 months (95% CI: 3.9-16.5) for chemo-naïve group and 10 months (95% CI: 7.4, 12.5) and 5.3 (95% CI: 4.3, 9.6) months for postchemo group, respectively [ Table 2 ]. Table 3 shows the treatment-related toxicities in patients treated with AA. We found the following common adverse events (all grades). Nausea 12 (20.3%), hypertension 11 (18.6%), fatigue 11 (18.6%), liver function abnormality 10 (16.9%), vomiting 7 (11.8%), hypokalemia 6 (10.1%), fluid retention 5 (8.4%), thrombocytopenia 3 (5.0%), and cardiac toxicity 2 (3.3%). Two patients required dose modifications due to thrombocytopenia and transaminitis each. Only three patients stopped abiraterone due to toxicity; the reason for it was fluid retention and cardiac toxicity. There was no grade 4 toxicity or treatment-related death among them.
Adverse events
Univariate analysis
In univariate analysis, the presence of the previous taxene used or not was the significant determinant of both OS and PFS with Abiraterone [ Table 4 ] with the P = 0.004 and 0.005, respectively. The presence of low Gleason score (hazard ratio [HR] 0.53, 95% CI: 0.33-0.85, P = 0.0086) was determinant of best PSA response. HR observed with other covariates such as initial PSA, performance status, stage at diagnosis, and baseline PSA are detailed in Table 4 .
Discussion
In a Phase 3, multicenter, randomized, placebo-controlled study by de Bono et al., [10] AA 1000 mg daily with prednisolone 5 mg BD has been shown to improves survival in patients with metastatic castration-resistant prostate cancer who have failed one or two prior chemotherapy regimens, one of which contained docetaxel. In addition, in a study done by Ryan et al., [11] AA with prednisolone has been shown to improve survival in chemotherapy naïve patient also. Till date, no data is available for the use of AA in Indian patients. Hence, we have planned for retrospective analysis of patients receiving AA in mCRPC from July 2013 to December 2015 at our tertiary care institute.
In this study, we reported the efficacy and toxicity of abiraterone in patients of mCRPC from an unselected patient population in a nontrial setting. The inclusion of all abiraterone treated patients at our institute during a defined period serves to provide a representative picture of the efficacy of abiraterone in real-world setting.
In our study, unexpectedly, the median PFS and OS of chemo-naïve patients were remarkably much shorter than that reported in COU-AA-302 study. [11] In contradiction to above in post chemo group we found the tolerability and PFS with abiraterone similar to what reported in COU-AA-301 study, however OS was found to be inferior similar to chemo naive group. [10] The reasons for this difference may be explained by relatively high tumor burden (which is supported by a higher median baseline PSA level) in our patient cohort, unselected patient population in contrast to clinical trial, nonaffordability for further lines of therapy and small sample size. In addition, many of our patients received (14 out of 59) prior ketokonazole, (patient group that was excluded in both COU-AA-301 and COU-AA-302 study, due to the potential overlapping mechanism of action) which has been shown to be associated with inferior outcome with Abiraterone. In a study by Kim et al. [12] on sequential use of the androgen synthesis inhibitors ketoconazole and AA in castration-resistant prostate cancer demonstrated modest clinical efficacy with abiraterone inpatients previously treated with ketoconazole [ Table 5 ]. Besides this, our study cohort included 85% of symptomatic patients when compared with COU-AA-302 study in which only asymptomatic or mildly symptomatic patients were included.
In our cohort, abiraterone effectively achieved a PSA response (≥50% PSA decline) in 15 (39.4%) chemotherapy-naive patients and 4 (18.1%) postdocetaxel patients. All biochemical responses were achieved within a median of 7 months of treatment. We found that achievement of the best PSA response after abiraterone is a favorable prognostic factor which is in consistency with prior studies. [10, 11] While the efficacy of abiraterone in with visceral metastases or symptomatic disease is not clear, our study suggests that patients with high tumor burden, visceral metastases may have inferior outcome with abiraterone in terms of PFS and OS.
In contrast, as seen in the subgroup analysis in the TAX 327 study the presence of symptomatic or visceral metastasis did not confer inferior clinical outcome to docetaxel-based chemotherapy. [13] With the lack of randomized trial specifically addressing this issue, the practice of using abiraterone in this particular subgroup should be further evaluated.
Limitations of the present study include the usual shortcomings of retrospective study such as under-reporting of adverse events, incompleteness of data collection and selection bias. However, these limitations should not affect the ability to calculate the survival outcome of abiraterone.
Conclusion
The present study reported the efficacy abiraterone in both chemo-naïve and postchemo patients of mCRPC outside clinical trial setting. We found lower OS and PFS with abiraterone as compared to that reported in the clinical trial setting in both chemo-naïve and postchemo patients, and particularly in those patients with visceral disease, and further clinical trial for abiraterone in this subgroup of patients is warranted.
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Immunotherapy has led to a paradigm shift in cancer therapy with a proportion of patients developing drastic and prolonged tumor response; however, tumor flare ups have been anecdotally described since the beginning days of immunotherapy. This was systematically studied first in an article by Champiat et al. who reported around 9% incidence of hyperprogression across various tumors in patients treated with PD1 and PDL1 inhibitors. [1] In their study, hyperprogressive disease (HPD) was defined as a RECIST progression at the first evaluation and as a >2-fold increase of the tumor growth rate between the reference and the treatment periods. It was observed that HPD had no relationship with tumor type or tumor burden and patients with HPD had shorter overall survival (OS). Interestingly, tumor growth rate preimmunotherapy was inversely related to response to immunotherapy and no patients treated with lung cancer had HPD in their study.
A study by Saâda-Bouzid et al. examined the same issue specifically in head-and-neck cancer patients. Here, patients treated with nivolumab and pembrolizumab (both PD1 inhibitors) were found to have 29% rate of hyper progression. [2] HPD was defined as Tumor Growth Rate constant (TGRk) >2 based on the graph of tumor growth rate. Again, it was observed that HPD is associated with shorter progression-free survival and OS. Atypical pattern of immune response in urothelial and renal cell cancer was investigated in a metaanalysis which observed hyperprogression in a substantial number of patients with bladder cancer and one patient with RCC. [3, 4] Hyperprogression has been reported in NSCLC treated with immunotherapy. There are two case reports of "tumor flare up" which is consistent with hyperprogressive disease in patients treated with nivolumab. [5, 6] Ferrara et al. did a retrospective study of 242 patients treated with various immunotherapies and found 16% hyper progression in NSCLC cases treated with immuno-oncologics (IOs). [7] There were no predictors of HPD in their study, including PDL1 level or tumor mutational burden. Similar to the previous studies, people with HPD were observed to have a shorter OS.
A single-institution study of hyperprogressors (five patients) observed two patients with MDM2/MDM4 amplification, 1 with epidermal growth factor receptor mutation and 1 with mutation in 11q13; all of them were treated with nivolumab or pembrolizumab. [8] The genomic profile of cancer patients with HPD was examined by Kato et al. in a larger retrospective study. [9] Consecutive Stage IV cancer patients who received immunotherapies 
